|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00002484 |
|
Date of registration:
|
01/11/1999 |
|
Primary sponsor: |
|
|
Public title:
|
Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer
|
|
Scientific title:
|
A PHASE I TRIAL OF DOSE ESCALATION OF EXTERNAL BEAM RADIATION THERAPY USING CONFORMAL 3-DIMENSIONAL TREATMENT PLANNING FOR NON-SMALL CELL LUNG CANCER |
|
Date of first enrolment:
|
October 1991 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00002484 |
|
Study type:
|
Interventional |
|
Study design:
|
Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Kenneth Rosenzweig, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Memorial Sloan-Kettering Cancer Center |
| | |
|
Key inclusion & exclusion criteria
|
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-small cell lung cancer
- Clinical stage T1-4, N0-2, M0
- Clinical stage T1-2, N0-1 must be medically inoperable
- No distant metastases on history and physical exam, CBC, screening profile, CT or MRI
of brain, CT of chest and abdomen (including adrenals and liver), and bone scan
- No pleural effusions
- Atelectasis not clearly distinguishable from tumor mass allowed provided all tumor
and atelectasis together represent a volume that can be safely treated to the total
dose delivered to gross disease
- Diffuse pulmonary infiltrates thought to represent benign disease allowed only if
representative lesion samples are proven by biopsy or cytology not to contain cancer
- No diffuse bronchoalveolar carcinoma
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 70-100%
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No other malignancy within the past 5 years except nonmelanomatous skin cancer or
noninvasive cervical carcinoma
- No other medical illness that cannot be adequately controlled with appropriate
therapy or that is considered severe enough to preclude a radical treatment approach
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy for lung cancer
Chemotherapy
- No prior chemotherapy for lung cancer
Endocrine therapy
- No prior endocrine therapy for lung cancer
Radiotherapy
- No prior radiotherapy for lung cancer
Surgery
- No prior surgery for lung cancer
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Lung Cancer
|
|
Intervention(s)
|
|
Radiation: radiation therapy
|
|
Secondary ID(s)
|
|
CDR0000077300
|
|
MSKCC-91121
|
|
NCI-V91-0198
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|